Gross Margin

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

The professional information giant posted robust 2025 earnings while ramping up AI investment and navigating a pivotal CEO transition. Here's what it means.

Vow ASA reports record Q4 revenues but shifts strategy to focus on its booming maritime sector, following major write-downs in its industrial division.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

The healthcare specialist reported a staggering 2025 net loss due to a write-down, but projects 30% revenue growth fueled by new contracts.

Heritage Insurance projects a stunning full-year return on equity over 45%, setting the stage for a blockbuster earnings report on March 9.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

All eyes are on Micron's March 18 report as a key test of the AI-fueled memory market recovery and the firm's strategic pivot to high-value tech.

onsemi will detail its long-term financial and innovation roadmap, focusing on capitalizing on AI, EV, and industrial megatrends amid fierce competition.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

The legacy brand blends heritage, market strategy, and conservation with its new 8-year bourbon, inspired by 19th-century decanters and now available nationwide.

PGA star Max Homa shares his hidden health battle with seborrheic dermatitis, urging millions to trade self-diagnosis for a doctor's visit.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

The shipping and printing giant's spot on a top global list highlights a stable model for entrepreneurs and its vital role in supporting small businesses.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

The powertrain giant crushed market expectations with a 29% revenue surge in 2025, fueled by heavy-duty engines, while eyeing a global and green future.